FDA Approved
2006
Viread
(Tenofovir) Inhibits viral DNA polymerase Gilead Sciences,
Foster City, CA FDA Approved 2008
Clevudine
(L-FMAU)
Inhibits viral DNA polymerase Bukwang,
South Korea
Eisai, Japan Approved S. Korea
2006 (Levovir)
Tenofovir alafenamide (TAF)
Prodrug of Tenofovir Gilead Sciences,
Foster City, CA Phase III
CMX157 Prodrug of Tenofovir ContraVir Pharmaceuticals,
Edison, NJ Phase II
AGX-1009 Prodrug of Tenofovir Agenix, Australia Phase I, China
Non-Nucleoside Antivirals - Interfere with proteins involved in viral reproduction
Myrcludex B Entry Inhibitor Hepatera, Russia with Myr-GmbH, Germany Phase II for HBV and HDV
ARC520 RNAi gene silencer Arrowhead Research, Pasadena, CA Phase II/III
NVR 3-778 Capsid inhibitor Novira Therapeutics, Doylestown, PA Phase IIa
Morphothiadine mesilate (GLS4) Capsid inhibitor Sunshine Lake Pharma of HEC, China
Phase II
IONIS-HBVRx (ISIS-HBVRx) Antisense drug ISIS Pharma (w/ GSK), Carlsbad, CA
Phase II
SB 9200 HBV Small molecule nucleic acid hybrids or “SMNH” Spring Bank Pharma,
Milford, MA
Phase II
Rep 2139-Ca HBsAg release inhibitor REPLICor Inc.,
Canada Phase II
AIC 649 (Bay 41-4109) Capsid Inhibitor AiCuris, Germany Phase I
TKM-HBV RNAi gene silencer Tekmira,
Canada
Phase I
IONIS-HBV-LRx (ISIS-GSK6-LRx) Ligand Conjugated Antisense (LICA) Technology ISIS Pharma (w/ GSK), Carlsbad, CA Phase I
Alinia (Nitazoxanide) Small molecule Romark Labs,
Tampa, FL Preclinical
CpAMS HBV Core Protein Assembly Biosciences, NY, NY Preclinical
ALN-HBV RNAi gene silencer
Alnylam,
Cambridge, MA
Preclinical
CPI-431-32 Cyclophilin inhibitor
Ciclofilin Pharma,
San Diego, CA
Preclinical
Hepbarna RNAi gene silencing
Benitec, Australia
Preclinical
Non-Interferon Immune Enhancers - Boost T-cell infection-fighting immune cells and natural interferon production
ABX 203 Therapeutic vaccine ABIVAX,
Paris, France Phase IIb/III
GS-4774 Therapeutic vaccine Gilead Sciences with Globe Immune,
Louisville, CO Phase II
GS-9620 TLR7 agonist Gilead Sciences,
Foster City, CA Phase II
RG7795 (formerly ANA773) TLR7 agonist Roche, Switzerland Phase II
CYT107
(Interleukin-7) Immunomodulator Cytheris,
France Phase I/IIa
INO-1800 Therapeutic vaccine Inovio,
Blue Bell, PA Phase I
NCT01641536 Therapeutic vaccine Ichor Medical Systems (w/Janssen), San Diego, CA Phase I
TG 1050 Immunotherapeutic Transgene,
Shanghai Phase I
CYT-003 TLR9 agonist Arbutus Biopharma (formerly Tekmira), Canada Preclinical
Hepatitis Delta Virus (HDV) Drug Watch
Myrcludex B Entry Inhibitor (Targeting NTCP) Hepatera, Russia with Myr-GmbH, Germany "Orphan Drug Designation" by US FDA and EMA for HDV
Lonafarnib Prenylation Inhibitor Eiger BioPharmaceuticals, Palo Alto, CA Phase II for HDV
Rep 2139 HBsAg Release Inhibitor REPLICor, Canada Phase II for